In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 33 for your search:

Drug:  oblimersen sodium
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase II/III Randomized Study of Docetaxel With or Without Oblimersen (Bcl-2 Antisense Oligonucleotide; G3139 ) in Patients With Previously Treated Non-Small Cell Lung Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: GENTA-GN304, NCI-G01-2046, UCLA-0301058, NCT00030641

Phase III Randomized Study of Dacarbazine With or Without Oblimersen (G3139) in Patients With Advanced Malignant Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENTA-GM301, UCLA-0207109, NCT00016263

Phase III Randomized Study of Dexamethasone With or Without Oblimersen in Patients With Relapsed or Refractory Multiple Myeloma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENTA-GMY302, UF-G-29-2001, NCT00017602

Phase III Randomized Study of Fludarabine and Cyclophosphamide With or Without Oblimersen (G3139, Genasense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENTA-GL303, UCLA-0104008, NCT00024440

Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 60 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02805, CALGB 10201, U10CA031946, CDR0000367323, NCT00085124

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AGENDA, GM307, NCT00518895

Phase I/II Study of Oblimersen With Docetaxel in Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumors (Summary Last Modified 12/2001). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MSKCC-97096, GENTA-G3139-97/01, NCI-G97-1337, NCT00003103

Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067529, SACI-IDD-98-32, UTHSC-IDD-98-32, NCI-T98-0094, T98-0094, NCT00004870

Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10117, UCCRC-10017, NCI-T98-0091, T98-0091, NCT00005032

10.

Phase I/II Study of Oblimersen in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENTA-GL208, MDA-ID-00337, NCT00021190

11.

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000271308, U01CA069853, P30CA054174, SACI-IDD-02-23, NCI-5793, 5793, NCT00055822

12.

Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01437, MC0285, N01CM17104, CDR0000304634, MAYO-MC0285, NCI-5826, 5826, NCT00062244

13.

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GL217, NCT00078234

14.

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02600, 12975A, N01CM62201, CDR0000371904, UCCRC-12975A, 6243, NCI-6243, NCT00086944

15.

Phase II Study of Oblimersen and Gemtuzumab Ozogamicin in Elderly Patients With Relapsed Acute Myeloid Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENTA-GA210, UCCRC-10928, NCT00017589

16.

Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02819, CALGB 30103, U10CA031946, NCT00042978

17.

Phase II Study of Oblimersen and Doxorubicin in Patients With Advanced Hepatocellular Carcinoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-011, NCI-5798, NCT00047229, 5798

18.

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Phase: Phase II
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02790, CALGB 10107, U10CA031946, CDR0000257816, NCT00049192

19.

Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-00617, ID02-148, N01CM17003, N01CM62202, N01CM17107, N01CM62203, MDA-ID-02148, NCI-5808, 5808, NCT00054639

20.

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02828, PHII-42, N01CM17101, CDR0000298756, CCC-PHII-42, CHNMC-PHII-42, NCI-5828, 5828, NCT00059813

21.

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01446, 03-105, N01CM62206, CDR0000354418, MSKCC-03105, NCI-5907, 5907, NCT00079131

22.

Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-30021, AVENTIS-AVE3139E/2501, NCT00085228

23.

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000258058, MSGCC-210421, NCI-5824, 5824, NCT00049374

24.

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0188, NCT01200342

25.

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01399, OSU-99H0257, OSU-9977, NCI-T99-0057, CDR0000067515, T99-0057, NCT00004862

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map